NCT05076981

Brief Summary

Natural cycles are evaluated during fertility treatments for different therapeutic options, like insemination (IUI), time intercourse (TI) or frozen-thawed embryo transfers (FET). Two possible protocols can be used for natural cycles, with or without hCG trigger. Usually, studies including natural cycles consider both options as equivalent, not considering the possible bias that the exogenous hCG (human chorionic gonadotrophin) might have. In this prospective study, Investigators aim to evaluate the differences in the hormonal profile during the ovulation when it occurs spontaneously vs triggered with a bolus of hCG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 20, 2021

Completed
3 days until next milestone

Study Start

First participant enrolled

September 23, 2021

Completed
20 days until next milestone

First Posted

Study publicly available on registry

October 13, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

March 14, 2023

Status Verified

March 1, 2023

Enrollment Period

3 months

First QC Date

September 20, 2021

Last Update Submit

March 13, 2023

Conditions

Keywords

luteal phasenatural cyclehuman chorionic gonadotropinprogesteroneprogesterone riseovulation

Outcome Measures

Primary Outcomes (1)

  • Difference in hormone levels

    Small sample data will be analyzed with the use of non-parametric test like Wilcoxon test to a paired a test of difference in hormones levels of the patients represented in both cycles (PNC and MNC) (dependent samples). This test will be preferred due to non-independent interval or ratio data in addition not to meet the normality or homogeneity of variances assumptions as paired t-test. Hormonal pattern over the days (measured for some days during cycle 1 and cycle 2) will be analyzed using trend analysis (line fit).

    35 days

Secondary Outcomes (2)

  • Number of visits in luteal phase

    17 days

  • Luteal phase length

    17 days

Study Arms (2)

Pure Natural Cycle

* Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1) * TVUS day 9-10 of cycle to identify dominant follicle. * Blood test for IVF1 every 24h until identification of the LH surge. * The LH surge will be diagnosed when the concentration rises by 180% above the latest serum value available in that patient and continued to rise thereafter (Fatemi et al, 2010). * Once the LH rise is detected, blood test for IVF1 to be performed after 2h, and then every 12h after LH rise for 2 days. * During luteal phase, IVF1 day 7 after LH rise and day 14 after LH rise.

Modified Natural Cycle

* Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1) * TVUS day 9-10 of cycle to identify dominant follicle. * Once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously. IVF1 to be performed just before the rhCG-administration. * IVF1 2h after rhCG. * IVF1 every 12h for 2 days after rhCG. * During luteal phase, IVF1 day 7 after rhCG and day 14 after rhCG.

Drug: human chorionic gonadotropin

Interventions

once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously

Also known as: Ovitrelle
Modified Natural Cycle

Eligibility Criteria

Age18 Years - 39 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailshealthy women with spontaneous ovulation
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

healthy women with spontaneous ovulation

You may qualify if:

  • Healthy women below 40 years
  • Regular and Ovulatory cycles

You may not qualify if:

  • Previous adnexal surgery
  • Endometriosis
  • PCOs
  • Using hormonal contraception during the previous 2 months: OCP, progesterone IUD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ART Fertility Clinics LLC

Abu Dhabi, 60202, United Arab Emirates

Location

Related Publications (5)

  • Licht P, Fluhr H, Neuwinger J, Wallwiener D, Wildt L. Is human chorionic gonadotropin directly involved in the regulation of human implantation? Mol Cell Endocrinol. 2007 Apr 15;269(1-2):85-92. doi: 10.1016/j.mce.2006.09.016. Epub 2007 Feb 14.

    PMID: 17367920BACKGROUND
  • Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.

    PMID: 20097333BACKGROUND
  • Kyrou D, Kolibianakis EM, Fatemi HM, Grimbizis GF, Theodoridis TD, Camus M, Tournaye H, Tarlatzis BC, Devroey P. Spontaneous triggering of ovulation versus HCG administration in patients undergoing IUI: a prospective randomized study. Reprod Biomed Online. 2012 Sep;25(3):278-83. doi: 10.1016/j.rbmo.2012.05.005. Epub 2012 May 23.

    PMID: 22796236BACKGROUND
  • Connelly LM. Pilot studies. Medsurg Nurs. 2008 Dec;17(6):411-2. No abstract available.

    PMID: 19248407BACKGROUND
  • Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008 Apr;31(2):180-91. doi: 10.1002/nur.20247.

    PMID: 18183564BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

serum

MeSH Terms

Conditions

Infertility, Female

Interventions

Chorionic Gonadotropin

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesInfertility

Intervention Hierarchy (Ancestors)

GonadotropinsPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPlacental HormonesPeptidesAmino Acids, Peptides, and ProteinsPregnancy ProteinsProteins

Study Officials

  • LAURA MELADO, PhD

    ART Fertility Clinics LLC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 20, 2021

First Posted

October 13, 2021

Study Start

September 23, 2021

Primary Completion

December 30, 2021

Study Completion

December 30, 2021

Last Updated

March 14, 2023

Record last verified: 2023-03

Locations